Bio-Rad Commercializing Lamprogen's Fluorescent Particles | GenomeWeb

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories announced after the close of the market on Thursday a commercialization deal with Lamprogen.

Lamprogen, a University of Washington spinout, has granted Bio-Rad exclusive rights to commercialize a class of bright, stable, and non-toxic fluorescent particles. The particles can be used in a broad array of assays and research applications including flow cytometry, Bio-Rad said, adding it expects to commercialize the products in 2013.

The deal also grants Bio-Rad access to future technologies developed by Lamprogen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.